Hemophilia Market Size, Growth Analysis, Growth Demand, Forecast To 2033

The hemophilia market size has grown strongly in recent years. It will grow from $12.59 billion in 2023 to $13.83 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to government initiatives, increased number of hemophilic patients, rising diagnostic screening, increasing awareness about hemophilia treatments.

The hemophilia market size is expected to see strong growth in the next few years. It will grow to $19.4 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising research and development hemophilias, rising diagnostic screening, incremental healthcare spending, global access to treatment. Major trends in the forecast period include new drug launches and approvals, escalation in novel drug development, research and clinical trials, digital health solutions, advancements in treatment options.

Market Overview -
Hemophilia is a rare genetic disorder that affects the body's ability to clot blood properly and generally occurs when a person gets injured and starts bleeding. Hemophilia treatment treats Hemophilia disease through various medical interventions and strategies to manage and address the bleeding tendencies associated with hemophilia.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12905&type=smp

Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth
The rising occurrence of genetic abnormalities is expected to propel the growth of the hemophilia market going forward. Genetic abnormalities, also known as genetic mutations or genetic disorders, refer to changes in the DNA sequence of an individual's genes that can result in various health conditions and physical traits. Hemophilia treatment aims to prevent or control bleeding episodes, minimize complications and improve the quality of life for individuals with genetic abnormalities. For instance, in June 2023, according to Gene People, a UK-based registered charity organization that supports genetic conditions, one in every 25 kids had a genetic disorder. Consequently, 30,000 new-borns and young children in the UK and more than 2.4 million children and adults are affected by a genetic disorder each year. Therefore, the rising occurrence of genetic abnormalities is driving the growth of the hemophilia market.

Competitive Landscape -
Major players in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Precision BioLogic Inc., Dimension Therapeutics, Chameleon Biosciences, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB.

Major Players In The Hemophilia Market Lead With Innovative Drugs Such As Altuviiio
Major companies operating in the hemophilia market are developing innovative drugs such as ALTUVIIIO to sustain their position in the market. For instance, in February 2023, Sanofi S.A., a France-based pharmaceutical and healthcare company, launched ALTUVIIIO for hemophilia, which was approved by The Food and Drug Administration (FDA), a US-based government agency. With once-weekly dosing, ALTUVIIIO is the first and only hemophilia A medication to offer regular to near-normal factor activity levels (above 40%) for most of the week and dramatically lessen bleeding compared to previous factor VIII prophylaxis.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Key Segments -

The hemophilia market covered in this report is segmented -

1) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
2) By Treatment: Replacement Therapy; Hemostatic Agents; Desmopressin; Gene Therapy; Other Treatments
3) By End-User: Hospitals; Clinics; Home Care Settings; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.